Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827472 | 1.00 | GPR3 (0.69) | GPR3KDM4ECYP3A4HPRT1MAPT | |
| SCHEMBL10025814 | 0.86 | KDM4E (0.55) | GPR3KDM4ECYP3A4HPRT1MAPT | |
| SCHEMBL19020845 | 0.84 | GPR3 (0.68) | GPR3KDM4ECYP3A4MAPTLMNA | |
| SCHEMBL29808357 | 0.82 | KDM4E (0.62) | GPR3KDM4ECYP3A4HPRT1MAPT | |
| SCHEMBL28054044 | 0.82 | KDM4E (0.62) | GPR3KDM4ECYP3A4HPRT1MAPT | |
| Phenanthridine SCHEMBL30914262 | 0.82 | GPR3 (1.00) | GPR3KDM4ECYP3A4MAPTLMNA | |
| Phenanthridine SCHEMBL8666 | 0.82 | GPR3 (1.00) | GPR3KDM4ECYP3A4MAPTLMNA | |
| Phenanthridine SCHEMBL30823553 | 0.82 | GPR3 (1.00) | GPR3KDM4ECYP3A4MAPTLMNA | |
| Phenanthridine SCHEMBL9106884 | 0.82 | GPR3 (1.00) | GPR3KDM4ECYP3A4MAPTLMNA | |
| SCHEMBL22062340 | 0.82 | KDM4E (0.47) | GPR3KDM4ECYP3A4HPRT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3244930-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIV SOUTHERN CALIFORNIA (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260083685-A1 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260069587-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12514828-B2 | Methods of permeabilizing the blood brain barrier | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-01-06 | — | — | US | disclosed |
| US-12508275-B2 | Neomycin based compounds, and pharmaceutical use thereof | UNIVERSITÉ COTE D'AZUR (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-4656641-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12419832-B2 | Intratumoral delivery of bortezomib | COGNOS THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250270293-A1 | SCAFFOLD PROTEINS | AVACTA LIFE SCIENCES LIMITED (GB) | 2025-08-28 | — | — | US | disclosed |
| US-12383621-B2 | Pharmaceutical compositions comprising POH derivatives | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250186472-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | Neonc Technologies, Inc. | 2025-06-12 | — | — | US | disclosed |
| WO-2004014918-A1 | NITRO AND AMINO SUBSTITUTED TOPOISOMERASE AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003051289-A2 | SOLUBILIZED TOPOISOMERASE POISON AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003047505-A2 | TOPOISOMERASE POISON AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-6486167-B1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-11-26 | — | — | US | disclosed |
| US-6140328-A | FOR TREATING TUMOR | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1042294-A1 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031067-A1 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0532515-B1 | PREPARATION OF SUBSTITUTED PIPERIDINES | PFIZER (US) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383621-B2 | Pharmaceutical compositions comprising POH derivatives | PDE3A, PDE3B, PDE5A | GPR3 526/4885KDM4E 215/4885CYP3A4 430/4885 |
| US-12508275-B2 | Neomycin based compounds, and pharmaceutical use thereof | BRCA1, NTRK3, EGFR | GPR3 974/4885KDM4E 4182/4885CYP3A4 2138/4885 |
| US-20250186472-A1 | COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS | CFH, AQP4, MAG | GPR3 2592/4885KDM4E 1282/4885CYP3A4 103/4885 |
| US-20250270293-A1 | SCAFFOLD PROTEINS | TRIM28, PHAX, KPNA1 | GPR3 3527/4885KDM4E 2276/4885CYP3A4 4631/4885 |
| US-20260069587-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | GCDH, PLIN3, PRPH | GPR3 1479/4885KDM4E 1771/4885CYP3A4 100/4885 |
| US-20260083685-A1 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | CD4, EPCAM, ICOS | GPR3 777/4885KDM4E 3878/4885CYP3A4 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.